-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Adds Three Drugs to China’s National Reimbursement List

PUBT·11/15/2026 10:37:59
Listen to the news
Hengrui Adds Three Drugs to China’s National Reimbursement List
  • Jiangsu Hengrui secured first-time inclusion of three drugs in China's 2026 National Reimbursement Drug List.
  • Two drugs gained coverage for new indications; seven others retained coverage through renewals.
  • The updated list takes effect January 1, 2027.
  • Sales of the affected drugs totaled approximately CNY 6.86 billion in the first three quarters of 2026.
  • Full-year 2025 sales of those drugs were approximately CNY 6.95 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261115-12413063), on November 15, 2026, and is solely responsible for the information contained therein.